Skip to main content
Home
Ora
  • About Us
  • Our Clients
  • Areas of Expertise
  • Clinical Models
  • Preclinical Models
  • Our Services
  • Contact
  • Careers
  • News & Publications
  • Posters
  • Events
  • Ora Investigator Network
  • Participate in a Clinical Trial
  • Ora Newsletter
Ora Japan
  • Allergic Rhinitis (24)
  • Allergy (71)
  • Anti-Infective (36)
  • Anti-Inflammatory (35)
  • Devices (27)
  • Drug Delivery (20)
  • Dry Eye (125)
  • Glaucoma (28)
  • Retina (68)
  • Corporate News (48)
  • Other Specialty (48)

Ora Newsletter Sign-up Today

Previous issues

Posters

  • Evaluation of the Effects of SkQ1 in Ora’s Rabbit Anterior Chamber Paracentesis Model
  • The effect of TRPM8-agonist Menthol Eyedrops on Tear Meniscus Area and Height
  • Reducing Nasal and Ocular Itching with a Novel Drug in the Allergen BioCube
more posters

Articles

  • Making Basic Science Studies in Glaucoma More Clinically Relevant
  • Ora Appoints Experienced Clinical Operations Leader Amid Strong Demand for Global Ophthalmology CRO Services
  • Veeva Vault CTMS Gains Momentum as Industry Moves to Unify Clinical Applications and Processes
more articles

All Posters

From Retina ARVO
Assessment of Macular Recovery Time after Photostress by Foveal L-Cone Dark Adaptation in Young...
ARVO - 2010
From Retina ARVO
Time trends in the Prevalence of Diabetic Retinopathy in Persons With Type 1 and Type 2 Diabetes
2009_ARVO_Time_Trends_in_the_Prevalence_of_Diabetic_Retinopathy.pdf
From Dry Eye ARVO
Symptomatic Break-up Time (SBUT) in Dry Eye Patients with Normal vs. Low Corneal Sensitivity
ARVO - 2009
From Dry Eye ARVO
Modification of Tear Film Break-up Pattern in the Controlled Adverse Environment (CAE) Model
2009_ARVO_Modification _of_Tear_Film_Breakup_Pattern.pdf
From Allergic Rhinitis ARVO
Evaluation of Daily Oculat and Nasal Allergic Signs and Symptoms During 4 Weeks of Ragweed Season...
ARVO - 2009
From Dry Eye ARVO
Effects of Lacrisery on the signs and symptoms of dry eye in contact lens wearers
ARVO - 2009
From Retina ARVO
Current Pipeline for Treatment of Diabetic Retinopathy
ARVO - 2009

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

© Ora, Inc. | 300 Brickstone Square Andover, MA 01810 | Privacy Policy | (978) 685-8900

About Us
  • Company Profile
  • Events
  • Management Team
  • News & Publications
  • Research and Development
Our Clients
  • In-licensing Partners
  • Large Biopharma
  • Mid-Size Biopharma
  • VC Firms and Investors
  • Virtual Biopharma
Areas of Expertise
  • Allergy
  • Allergic Rhinitis
  • Anti-Infective
  • Anti-Inflammatory
  • Devices
  • Drug Delivery
  • Dry-Eye
  • Glaucoma
  • Retina
Our Services
  • Biostatistics
  • CMC
  • Consulting
  • Data Management
  • Medical Communications
  • OraNet
  • Subject Recruiting
  • Preclinical
  • Regulatory Consulting
  • Regulatory Writing
  • Statistical Consulting
Clinical Models
  • Allergen BioCube
  • Conjunctival Allergen Challenge (CAC® )
  • Conjunctival Biopsy
  • Controlled Adverse Environment (CAE® )
  • Enhanced Environmental Trial
  • Enviro-CAC
  • IVAD
  • Ocular Protection Index
  • Ora Calibra®
  • Lid Margin Disease Digital Image Grading System
  • Lid Swelling Scales
Contact
  • Careers
  • Directions
  • How can we help
  • Privacy Policy